Biweekly Dosing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biweekly Dosing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biweekly Dosing Today - Breaking & Trending Today

Johnson & Johnson : Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

Published: June 5, 2023

News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 ... | June 5, 2023

Source: marketscreener.com

Related Topics:

Noord HollandUnited StatesRachel KobosSatu GlaweChristie CorbettEuropean CommissionJanssen Oncology ResearchAmerican Society Of Clinical OncologyNational Comprehensive Cancer NetworkEastern Cooperative Oncology GroupInternational Myeloma Working GroupJanssen Pharmaceutical Companies Of JohnsonNews ReleasePresents Longer Term DataPatients AchievedOverall ResponseComplete ResponseJanssen Pharmaceutical CompaniesClinical OncologyAnnual MeetingConfidence IntervalAmsterdam University Medical CentersSuggest Durable ResponsesBiweekly DosingVice President

Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

Published: June 5, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing...

Source: prnewswire.com

Related Topics:

Noord HollandUnited StatesRachel KobosSatu GlaweChristie CorbettEastern Cooperative Oncology GroupExchange CommissionNone Of The Janssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonEuropean Medicines AgencyJanssen Pharmaceutical CompaniesEuropean CommissionAmerican Cancer SocietyAmerican Society Of Clinical OncologyNational Comprehensive Cancer NetworkJanssen Research DevelopmentCompanies Of JohnsonInternational Myeloma Working GroupJanssen Oncology Research DevelopmentOther Administration ReactionsNational Cancer InstituteClinical OncologyAnnual MeetingConfidence IntervalNot Evaluable